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Exposure to a wide variety ofantigens in ambient air takes place almost continu-
ouslyviathelung. As themainpart ofthese antigens aretrivial andonlythe minority
is potentially pathogenic, the immune response in the lung needs to be tightly con-
trolled in order to avoid obstruction of normal lung functioning.
In addition to an effective mechanical protection in airways, such as the nasal
filter, bronchial cilia, mucus, and surfactant, the respiratory tract is also protected
by an elaborate immunological defense system. Large populations oflymphocytes
can be found dispersed throughout lung tissue (1-4) and in specialized compart-
ments, like bronchus-associated lymphoid tissue (5) and draining lymph nodes. In
addition to this, nonlymphoid dendritic cells(1, 6, 7), bronchial and interstitial mac-
rophages, and alveolar macrophages (AM)' (1, 2, 8, 9) are present in the respira-
tory tract.
TheAMhave been assigned animportant role inremoving antigen from thelungs
by nonspecific phagocytosis, leading to transportation of these antigens, incorpo-
rated in the AM, up the mucociliary escalatorout ofthe lung. Apart from this scav-
enger role, there is evidence that AM play a role in particle transportation to the
lung-associated lymph nodes (LALN) (10). Furthermore, it is becoming clear that
the AM can play a regulatory role in the antigen presentation by dendritic cells in
lung tissue (6, 11, 12) or LALN (10, 13), as well as in the antigen-specific activation
of T and B lymphocytes. Therefore, AM could perform a key role in controlling
the pulmonary immune response, forwhich their anatomical position, strategically
situated at the air-tissue interface, is also suggestive (14). Many in vitro studies with
isolated AM have been performed, but they provide no unequivocal results con-
cerning this specific function (8, 14, 15).
To studythe in vivo role ofAM, we adapted a method, whichhas been developed
forthe elimination ofspleen macrophages (16), toeliminate AM. Usingthis method,
we were able to remove AM from the lung ofan intact animal, and it is shown that
this depletion leads to a significant increase in the pulmonary immune response to
an intratracheally administered antigen.
1 Abbreviations used in thispaper: AFC, antibody-forming cells; AM, alveolar macrophages; C12MDP,
dichloro-methylene-diphosphonate; LALN, lung-associated lymph nodes; TNP-AF, alkaline phospha-
tase-coupled trinitrophenyl; TNP-KLH, trinitrophenyl-keyhole limpet hemocyanin.
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Materials and Methods
Animals.
￿
(C3D2)F, mice were purchased from Bomholtg&rd Ltd., Ry, Denmark. The
mice were derived from a pathogen-free colony and were maintained in our facilities under
clean conditions in isolated rooms with acidified drinking water. The mice were used in the
experiments when 6-8 wk old.
Liposomes.
￿
The liposomes were composed of phosphatidylcholine and cholesterol (molar
ratio 6:1) and contained either PBS, or dichloro-methylene-diphosphonate (Cl2MDP) dis-
solved in PBS (0.189 g/ml). They were prepared as described before (16), in short: 86 mg
phosphatidylcholine and 8 mg cholesterol were dissolved in 10 ml chloroform, and by low
vacuum rotary evaporation a lipid film was produced, which was dissolved in either 4 ml
PBS or 10 ml C12MDP The suspension was kept at room temperature for 2 h, after which
it was sonicated for 3 min in a waterbath sonicator and again kept for 2 h at room tempera-
ture. The C12MDP liposome suspension was then diluted in 100 ml PBS and centrifuged
at 100,000 g for 30 min to remove free C12MDP, after which the liposomes were resuspended
in 4 ml PBS.
Administration ofLiposome Suspension or Antigen.
￿
The mice were fixed in an upright position
under total anesthetization with 40 I1 of a 4:3 mixture of Aescoket (Aesculaap N. V., Gent,
Belgium) and Rompun (Bayer, Leverkussen, FRG), intramuscularly injected. Using a nylon
tube, connected to a 1-ml syringe fixed in a micro-manipulator, 100 pl ofliposome suspension
or antigen was administered through the glottis into the trachea.
Immunization Procedure.
￿
Animals received 80 hg trinitrophenyl-keyhole limpet hemocyanin
(TNP-KLH) via the trachea, as described above, dissolved in 100 I1 PBS. At different in-
tervals the animals were killed and different organs were removed and used for histocytochem-
istry or in plaque-forming cell assay.
Detection ofLung Macrophages: Tissue Sections.
￿
The lungs were removed and vacuum fixed,
immersed in paraformaldehyde/lysine fixative (17), for 45 min. They were transferred to 20%
sucrose, snap frozen in liquid nitrogen, and cut in 8-Am sections on a cryostat (-20°C). The
sections were thereupon stained for acid phosphatase activity (18).
Detection of Lung Macrophages: Quantification of Interstitial Lung Macrophages.
￿
To determine
the effect of the CL2MDP and PBS liposomes on the interstitial macrophage population,
animals received either type of liposomes. 2 d later the animals were anesthesized with 75
Al Hypnorm (Janssen Pharmaceutica B. V., Tilburg, The Netherlands), and the thorax was
opened. The pulmonary vasculature was perfused with 10 ml PBS at 37°C, containing 500
pl thromboliquine (Organon Teknika B. V., Boxtel, Holland) per liter PBS, through the right
ventricle of the heart after severing the aorta. The lungs were removed if they appeared pale
white and were lavaged with 0.6 mM EDTA in PBS at 37 °C. The first two washings were
performed with 0.5 ml lavage fluid, after which nine others followed of 1 ml each. The lungs
were then minced and incubated in 10 ml RPMI 1640 containing 229 U ofcollagenase (Cooper-
Biomedical, Inc., Malvern, PA) and 0.1 mg/ml DNase (grad. II, lot no. 10912321-30; Boehringer
Mannheim FRG) for 90 min at 37°C under constant agitation. The cells were collected,
gently suspended through a nylon gauze, and washed three times in RPMI 1640 containing
5 % FCS. To determine the percentage ofmacrophages in the thus-prepared lung suspension,
the cells were stained with MOMA-2, an mAb specific for tissue macrophages (19). The number
of MOMA-2-positive cells was determined by analysis with a FAGS (FACStar, Becton Dick-
inson & Co., Mountain View, CA) in combination with an FITC-labeled rabbit anti-rat
(Fab)2 antiserum. In addition to this, cytocentrifuge preparations were made of the lung sus-
pensions, which were stained for acid phosphatase activity (18).
Detection of TNP. Specific Antibodyforming Cells.
￿
Spleen, LALN, and lungs were removed
and snap frozen by immersion in liquid nitrogen, cut in 8-,Um sections on a cryostat, and
fixed with acetone for 10 min. The presence of TNP-specific, antibody-forming cells (AFC)
was histochemically determined according to Claassen and Van Rooijen (20), using alkaline
phosphatase-coupled TNP (TNP-AF) as conjugate. Alkaline phophataseactivity was demon-
strated using naphtol AS MX phosphate as substrate and fast blue BB base as chromogen,
resulting in blue staining of TNP-specific AFC (18, 20). The slides were thereafter lightly
counterstained with hematoxiline and embedded in gelatine.
Plaqueforming CellAssay.
￿
The numberofTNP AFC and the isotype ofthe produced TNPTHEPEN ET AL .
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antibodies in LALN was determined by direct (IgM) and indirect (IgG, IgA, IgE) plaque-
forming cell assays (21) . TNP was coupled to SRBC according to Naor et al . (22), and these
cells were used as indicator cells in the plaque-forming cell assay . The isotype-specific anti-
IgE, -IgA, and -IgG antisera were kindly donated by Dr. H . Savelkoul, Erasmus University
Rotterdam, The Netherlands .
Results
In mice, elimination of splenic macrophages can be accomplished by an intrave-
nous injection with 200 p,l of liposome-encapsuled C12MDP (16) . Using the same
C12MDP liposomes, we injected mice intratracheally with 100 pl liposome suspen-
sion to see ifthiswould lead to elimination of theAM . Because ofthe use ofvacuum
fixation, we were able to make a clear distinction between alveolar and interstitial
macrophages on the basis oftheir anatomical localization in acid phosphatase-stained
lung sections . Under normal fixation conditions this distinction is hard to make,
owing to the collapse of lung tissue .
When the micewere examined for the presence ofAM, it was found that already
within 2-3 h after a single dose of 100 p,l C12MDP liposomes, allmost allAM were
depleted (Fig . 1 B), except for an occasionalAM in the smaller lung lobes . At day 5
after administration, someAM could be found returning, but complete repopulation
of the lung withAM was only reached around day 18 . In contrast, animals treated
with PBS liposomes showed normalAM populations throughout the period exam-
FIGURE 1 .
￿
Microphotographs showing alveoli in lung ofmice, stained for acid phosphatase ac-
tivity. (A) Alveoli of a control mouse, demonstrating numerous AM (arrows) . (B) Alveoli of a
mouse 2 d after intratracheal injection withC12MDP liposomes, note the absence ofAM (x 40) .502
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ined (Fig. 1 A). It was furthermore found that the C12MDP liposome treatment had
no effect on the number and location of interstitial macrophages. C12MDP and PBS
liposome-treated groups showed identical percentages of interstitial macrophages
(Table 1). This was supported by the acid phosphatase-stained lung sections, which
displayed normal interstitial macrophage populations (compare Fig. 1, A and B).
Administration of PBS liposomes in a solution of free C12MDP in PBS, up to 10
times the amount encapsulated in the injected liposomes, or free C12MDP alone in
the same concentration had no effect on the alveolar or interstitial macrophage popu-
lations either (results not shown).
To study whether this elimination of AM from the lung would influence the pul-
monary immune response, we immunized animals intratracheally with TNP-KLH
2 d after liposome treatment. At this timepoint, the lungs of C12MDP liposome-
treated animals were devoid ofAM (Fig. 1 A) and the animals were then considered
to be AM-depleted animals.
The formation of specific TNP-AFC in both AM-depleted and control animals
at various timepoints after immunizations is depicted in Table II . In both groups
TABLE I
The Effect of C12MDP or PBS Liposome Treatment on the
Interstitial Macrophage Population
Liposome treatment
￿
MOMA-2
￿
AP
C12MDP
￿
3.36 (t 0.56)
￿
3 .49 (t 0.86)
PBS
￿
3.07 (t 0.74)
￿
2 .85 (t 0.47)
Indicated are the mean percentages of positive cells ( t SEM) in lung suspen-
sions from five individual animals per group, as determined by FAGS analysis
of MOMA-2 staining, or countings of cytocentrifuge preparations stained for
acid phosphatase activity. AP, acid phosphatase activity; C12MDP: C12MDP/
liposome-treated animals; PBS: PBS/liposome-treated animals.
TABLE II
The Effect of AM Elimination on the Pulmonary Immune Response
PBS
At several intervals after intratracheal administration of TNP-KLH, the num-
ber of TNP-specific AFC was determined in a semi-quantitative manner. Each
group contained two to four animals. The response is represented as the num-
ber of AFC per section of either lung, lung-associated lymph node, or spleen.
No AFC detectable, - , 1-10, + / - , 10-50, + , 50-100, + +, 100-200, + + +,
>200 AFC per section, + + + + . Cl2MDP, C12MDP/liposomes-treated
animals; PBS, PBS/liposomes-treated animals.
Days after
immunization
Lung
C12MDP PBS
LALN
C12MDP PBS
Spleen
C12MDP
4 - - - - -
8 +/- - + + +-
11 + + - + + +/- -
13 + - + - -
15 + - + - -
28 + ND +/- ND NDTHEPEN ET AL .
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AFC are primarily found in theLALN . It is conspicuous, however, that compared
with thefewAFC foundin control mice, thenumber ofTNP-specificAFC in LALN
ofAM-depleted mice hasincreased dramatically (compare Fig . 2,A and B) . In addi-
tion, the immune response in LALN of AM-depleted mice is also longer lasting
than that in control mice, and even on day 28 after immunization, TNP-specific
AFC can still be found.
In control mice, specific AFC canbefound in LALN, albeit in lownumbers, but
there is no accumulation of TNP-specific AFC in the lungs of these animals for the
FIGURE 2 .
￿
Microphotographs fromLALN ofmice, intratracheally immunized with 80 ug TNP-
KLH 2 d after liposome treatment, stained to reveal TNP-specific AFC, and lightly counter-
stained with hematoxiline (x 10) . (A) LALN of a control mouse, 8 d after immunization, dis-
playing few TNP-specific AFC, mainly located in the medulla . (B) Numerous TNP-specificAFC
that are foundmore dispersed throughout theLALN ofan AM-depleted mouse, 8d afterimmu-
nization .504 ALVEOLAR MACROPHAGES AND THE PULMONARY IMMUNE RESPONSE
period tested (Fig . 3 A) . In contrast, numerous TNP-specific AFC can be found in
infiltrates around blood vessels in the AM-depleted animals . The first are found on
day 8 around large blood vessels (Fig. 3 B), while from day 13, TNP-specific AFC
are found more dispersed throughout the lung. In spleen no response is found at
any timepoint, nor in the AM-depleted, nor in the control animals .
The plaque-forming cell assays performed with lymphocyte suspensions of the
LALN clearly confirmthese results.A dramatic increase innumber ofPFC is found
in LALN ofAM-depletedanimals compared with control animals (Fig. 4) . The re-
FIGURE 3 .
￿
Microphotographs from lung of mice intratracheally immunized with 80 ug TNP-
KLH 2 d after liposome treatment, stained to reveal TNP-specific AFC, and lightly counter-
stained with hematoxiline (x 10) . (A) Lung from a control mouse, 11 d after immunization, in
which no TNP-specificAFC can be demonstrated (x 1.6) . (B) Lung ofan AM-depleted mouse,
11 d after immunization; note the numerous TNP-specific AFC (arrows) situated in infiltrates
around the major blood vessels .a 0
X
a
x
E
0
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FIGURE 4.
￿
Kinetics of appearance of TNP-KLH-
specific AFC in LALN, 4, 7, 10, and 13 d after in-
tratracheal administration of 80 jug TNP-KLH. 2 d
before immunization, animalswere pretreated with
PBS liposomes (A) or C12MDP liposomes (B).
NumbersofAFCwere determined usingdirect (IgM)
and indirect (IgG, IgA, IgE) plaque-forming cell
assay(23),usingTNP-SRBCs as indicator cells (24).
Data points represent mean values (t SEM) andeach
data point represents three experiments.
sponse in the AM-depleted and control mice show the same kinetics and there seems
to be no change in isotype specificity between the two groups. The majority of the
antibodies in both experimental groups consist of IgG, followed by IgA, and IgE,
andvery little IgM antibodies are found. Again, as alreadyseen in thehistochemical
demonstration of AFC, virtualy no PFC were found in the spleen of these animals
(results not shown).
Discussion
The resultsof the elimination experiments clearly show that liposome-encapsuled
C12MDP is capable of eliminating AM when injected intratracheally. The C12MDP
liposomes are phagocytized, and after digestion of the liposomal membranes, the
C12MDP is released into the cell. This leads to the rapid death of the cell by a mech-
anism that is still obscure, but may be related to the calcium-binding activity of
the molecule or the presence of chloride ions. Liposome-encapsuled C12MDP thus
selectively kills actively phagocytizing macrophages. It is evident that the liposomes
themselves have no influence on the AM population and that free C12MDP, which
might leak out of the liposomes, has no determinable effect either. In addition to
this, it was established that lung suspensions of both C12MDP and PBS lipo-
some-treated animals contained the same percentage of macrophages as found by
others in nonliposome-treated mice (23), so the interstitial macrophage population
remains unaffected after the elimination procedure.
From these results the conclusion can be drawnthat intratracheal administration
of C12MDP liposomes results in the specific elimination of AM from the lung in
mice, creating a test system that can be used to study the in vivo effect of AM.
In concordance with other experiments concerning lung immunization (24-26),506
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the control animalsonly showed alow immune response in LALN afterintratracheal
immunization. The outcome ofthe immunization experiments with AM-depleted
animals, in which a drastic increase in AFC in LALN and an introduction ofTNP-
AFC inlung is observed, compared withthe controlanimals, points to a suppressive
effect of the AM on the pulmonary immune response in vivo.
The strongly enhanced pulmonary immune response, found after AM elimina-
tion, can be explained in several ways. To some extent it can be accounted for by
a diminished antigen clearance from the lung, normally performed by AM. How-
ever, no significant increase in response was found afterincreasing the antigen dose
up to 10-fold in control animals (results not shown).
The adjuvant effect of liposomes has been described previously in immune re-
sponses against liposome-associated antigens, i.e., antigens encapsulated in theaqueous
compartment orexposed on thesurface ofthe liposomes(27). Such liposome-adjuvant
action cannot explain the increase ofthe pulmonary immune response since lipo-
somes and antigen were administered with a 2-d interval and, more importantly,
control animals were always treated with PBS liposomes.
Another possibility that might underly the observed increase is the release ofam-
plifying cytokines in the alveolar space from the perishing macrophages after
C12MDP treatment. Although this may play a part, AM have been reported to pro-
duce predominantly suppressive factors, such as prostaglandine E2 and only rela-
tively small amounts of positive factors, like IL-1 (15, 28).
It is therefore more likely that the increase in response is caused by the lack of
a regulatory, suppressive role ofthe AM. It has been demonstrated that the acces-
sory activity oflung-derived dendriticcells in T cellactivation, both in sodium peri-
odate-induced proliferation (12), as well as in response to antigen (6, 11), can be
suppressed by endogenous macrophages. This suppression is exercised by excretion
of soluble "suppressive" factors, like prostaglandines, or direct cell-cell contact (6,
14). Therefore, when such a suppressive effect by endogenous macrophages is
abrogated, as may be the case after AM elimination by C12MDP liposomes, this
could result in an enhanced presentation of invading antigens and enhanced T cell
activation, leading to an increase in pulmonary immune response, as seen in our
experiments.
For aproper initiation ofthepulmonary immune response, it is atpresent consid-
ered necessary that the antigen should be transported to the LALN (24). Although
such transportation function has been established for AM (10, 13), it could well be
that other cells involved in transportation or the actual presentation, like neutro-
phils (29) and possibly dendritic cells (6, 7), are regulated by AM. The here-found
increase in response after AM depletion would, in the scope of this theory, point
to either an AM-mediated suppressionofantigen presentation ofthe other celltypes
involved in transportation, or an evocation ofa suppressor mechanism, possibly in-
volving T cells, by the AM under normal physiological conditions. Whether AM
play a role in the induction ofTs cells has not yet formally been demonstrated . That
such antigen- andisotype-specific Tscells can arisein LALNofrats hasbeen demon-
stratedafter repeated aerosol antigen exposure (30). It may now be feasible to study
the role of AM in this induction in AM-depleted mice.
The results presented here demonstrate that the presence ofAM may be an im-
portant prerequisite for thedownregulation ofimmune responses in thelung-LALNTHEPEN ET AL.
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system under normal, steady-state conditions. Perturbation of the function of AM
may result in vigorous pulmonary immune responses that affect the normal physi-
ology and function of the lung.
The exact mode of operation of AM in controlling the pulmonary immune re-
sponse remains to be revealed. The model of AM-depleted mice as presented in
this paper may be of use in solving this problem.
Summary
A single intratracheal dose of liposome-encapsuled dichloro-methylene-diphos-
phonate resulted in the elimination of alveolar macrophages (AM) from the lung,
creating a model to study the in vivo role ofAM in the pulmonary immune response.
Using intratracheally administered trinitrophenyl-keyhole limpet hemocyanin
(TNP-KLH), the kinetics of the response, the location and number ofTNP-specific
antibody-forming cells, and the different Ig classes ofthe antibodies produced were
studied in AM-depleted animals.
The results show that AM elimination has a dramatic effect on the pulmonary
immune responses against TNP-KLH. An increase in APC in lung-associated lymph
nodes and a prolongation of the response is found, as well as an introduction of
APC in lung tissue. In both experimental groups, the majority of the TNP-specific
antibodies produced was IgG, followed by IgA and IgE, while very few IgM anti-
bodies could be detected.
We conclude from these results that AM are likely to play a role in controlling
the pulmonary immune response in a suppressive way, thereby limiting the possible
damage caused by severe immune responses in lung tissue.
Receivedfor publication 12 January 1989 and in revisedform 4 May 1989.
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